Table 3.
Pharmacokinetic parameters.
| Milvexian only (n = 16) |
Milvexian co-administered with single-dose rifampin (n = 16) |
Milvexian following repeated doses of rifampin (n = 16) |
|
|---|---|---|---|
| Cmax, ng/mL | 599 (526, 682) | 659 (560, 775) | 132 (119, 147) |
| AUC(0–T), ng·h/mL | 6153 (5383, 7032) | 6293 (5277, 7505) | 923 (799, 1067) |
| AUC(INF), ng·h/mL | 6248 (5462, 7148) | 6324 (5304, 7541) | 958 (837, 1097) |
| Tmax, h | 3.50 (2.00–8.00) | 3.54 (1.00–6.13) | 4.00 (3.00–6.00) |
| T1/2, h | 13.21 (4.075) | 8.83 (2.505) | 8.85 (2.512) |
Cmax, maximum observed plasma concentration; AUC(0–T), area under the plasma concentration–time curve from time 0 to time of last quantifiable concentration; AUC(INF), area under the concentration–time curve from time 0 extrapolated to infinite time; Tmax, time of maximum observed plasma concentration; T1/2, terminal plasma half-life; CI, confidence interval; SD, standard deviation.
Cmax, AUC(0–T), and AUC(INF) are presented as adjusted geometric mean (90% CI).
Tmax is presented as median (minimum–maximum).
T1/2 is presented as mean (SD).